Important Notice for Allarity Investors
Attention investors! Glancy Prongay & Murray LLP wants to remind everyone involved with Allarity Therapeutics, Inc. about an upcoming deadline for lead plaintiff motions. If you bought Allarity’s stock during certain time frames, now’s the time to take action.
Deadline Details
The deadline to file a lead plaintiff motion is fast approaching—note November 12, 2024, in your calendars! If you purchased shares of Allarity from May 17, 2022, to July 19, 2024, and experienced losses, this could affect you.
Options for Financial Recovery
If you’ve faced financial losses due to your investment in Allarity, you have options. Feel free to contact GPM for assistance and information on recovery actions available under federal securities laws.
Significant Events Impacting Allarity
On February 6, 2023, Allarity encountered a major event when it revealed that the SEC had requested documents from them. This situation suggested possible federal securities law violations concerning their submissions and communications with the FDA regarding the New Drug Application (NDA) for Dovitinib.
Stock Price Reactions
After this news broke, Allarity’s stock price fell to $0.228 per share, marking a 3.8% decline, reflecting investors' concerns about the investigation's developments. Matters worsened further after the December announcement concerning the removal of their CEO, resulting in a 13.4% drop, bringing shares down to $0.486 per share.
Ongoing Concerns from SEC Notifications
On July 22, 2024, Allarity faced more turmoil when it received a Wells Notice from the SEC. This notice indicated that former executives were under scrutiny regarding the NDA for Dovitinib. As a result, the company’s share price fell again, decreasing by 2.4% to $0.164 per share, continuing the pattern of financial challenges amid this evolving situation.
Class Action Allegations
The class action lawsuit encompasses several serious allegations against Allarity's management. It contends that during the Class Period, misleading statements were made about the company’s regulatory outlook and that crucial adverse information was not disclosed. Investors should consider how these aspects could impact their investment decisions significantly.
Steps to Take Action
For those looking to navigate this difficult scenario, it’s essential to act before the upcoming deadline. Investors interested in joining the class action should reach out to GPM directly for guidance on proceeding with claims and understanding their rights in this ongoing matter.
Frequently Asked Questions
What does the class action lawsuit entail?
The class action lawsuit concerns allegations that Allarity misled investors about its business operations and the regulatory status of its critical drug application.
What is the deadline to submit a lead plaintiff motion?
The deadline for submitting a lead plaintiff motion in this case is November 12, 2024.
How can I get in touch with Glancy Prongay & Murray LLP?
You can call them at 310-201-9150 or Toll-Free at 888-773-9224 for any questions related to your investment rights.
What could be the outcome of the lawsuit?
The outcome could provide potential financial recovery for investors who incurred losses due to the company’s actions during the class period.
Are there risks for investors in Allarity?
Yes, the ongoing investigations and current class action suggest a higher risk for investors concerning the stability of their investments in Allarity.
